SeniorJournal.com - Daily News for Senior Citizens

  FRONT PAGE • Aging • Health • Alzheimer's - Mental • Nutrition • Medicare & Medicaid • Politics  • Fitness  • Social Security • Alerts • Sex Health • Features • Retirement • Elder Care  >Search  >Senior Links

Aging News & Information

 
 

 

Aging News & Information

War Against Aging Heats Up with Calico, AbbVie Joint Effort

Google-backed Calico to create leading R&D facility in San Francisco focused on aging, age-related diseases

Sept. 4, 2014 – There was a major announcement in the war against aging yesterday as Calico, the Google-backed life sciences company, and AbbVie, a global, research-based biopharmaceutical company, announced a collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer.

The agreement also paves the way for Calico to establish a "world-class" research and development facility in the San Francisco Bay Area, according to the statement.  

Calico is led by Arthur D. Levinson Ph.D. (former chairman and CEO of Genentech) and Hal V. Barron, M.D. (former Executive Vice President and Chief Medical Officer of Genentech).

Under the agreement, the companies will combine their complementary strengths to accelerate the availability of new therapies for age-related diseases:

…. Calico will use its scientific expertise to establish a world-class research and development facility, with a focus on drug discovery and early drug development

…. AbbVie will provide scientific and clinical development support and its commercial expertise to bring new discoveries to market

"This collaboration demonstrates our commitment to exploring new areas of medicine and innovative approaches to drug discovery and development that augments our already robust pipeline," said Richard A. Gonzalez, Chairman of the Board and Chief Executive Officer, AbbVie. 

"We are pleased to be working with such outstanding scientists as Art Levinson, Hal Barron and their team.  The potential to help improve patients' lives with new therapies is enormous."

"Our relationship with AbbVie is a pivotal event for Calico, whose mission is to develop life-enhancing therapies for people with age-related diseases.  It will greatly accelerate our efforts to understand the science of aging, advance our clinical work, and help bring important new therapies to patients everywhere," said Art Levinson, CEO and founder of Calico.

 

Related Archive Stories

 

 

Google’s Calico to Use ‘Moonshot Thinking’ to Improve Life for Millions of Aging People

New company will focus on health and well-being to better meet the challenges of aging

Sept. 19, 2013


Read the latest news on

Aging

 

Details of the Research Collaboration

-      AbbVie and Calico will each initially provide up to $250 million to fund the collaboration with the potential for both sides to contribute an additional $500 million

-      Calico will be responsible for research and early development during the first five years and continue to advance collaboration projects through Phase 2a for a ten year period

-      AbbVie will support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the option to manage late-stage development and commercial activities

-      Both parties will share costs and profits equally

"We are thrilled to have the opportunity to work with the many outstanding scientists at AbbVie to ensure that the important science at Calico is advanced quickly to benefit patients," said Hal Barron, M.D., President of Research and Development at Calico.

"We are extremely proud to have our research teams partnering with Calico as we aim to address treatments for diseases of aging," said Michael Severino, M.D., Executive Vice President, Research and Development, and Chief Scientific Officer, AbbVie.

"Our broad R&D experience and capabilities will complement Calico's biotechnology expertise and innovative scientific approaches. Together, we are confident that we will bring new therapeutic solutions to patients."

Calico expects to begin filling critical positions immediately and plans to establish a substantial team of scientists and research staff in the San Francisco Bay Area.

About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

About Calico
Calico (California Life Sciences LLC) is a Google-founded research and development company whose mission is to harness advanced technologies to increase our understanding of the biology that controls lifespan. We will use that knowledge to devise interventions that enable people to lead longer and healthier lives. Visit www.calicolabs.com.

 

Financial Relief for Volkswagen Diesel Owners

You may be eligible for money damages if you owned or leased one of these VW, Porsche or Audi vehicles.

In the major scandal of 2015, Volkswagen cheated you and the world. They rigged diesel emission controls so you, nor regulators, would know how much pollution their cars were adding to our environment.

They were caught and have reserved $7.3 billion to help "make it right" with victims.

If you owned or leased one of these vehicles, contact us now.

 Beth Janicek, Board Certified Personal Injury Attorney Janicek Law attorneys are actively pursuing these cases against VW. Do Not Wait...

Janicek Law Firm, PC

Free Consultation

(Call toll free)

1-877-795-3425 or Email

Vehicles Involved

VW Jetta (2009–2015)

VW Jetta SportWagen (2009–2014)

VW Golf (2010-2015)

VW Golf SportWagen (2015)

VW Beetle (2012–2015)

VW Passat (2012-2015)

Audi A3 (2010-2015)

VW Touareg (2009–2016)

Porsche Cayenne (2015)

Audi A6, A7, A8, Q5 Quattro (2016)

 

Search for more about this topic on SeniorJournal.com

Google Web SeniorJournal.com

    

 

Published by New Tech Media - www.NewTechMedia.com

Other New Tech Media sites include CaroleSutherland.com, BethJanicek.com, SASeniors.com, DrugDanger.com, etc.